Immutrin, a Cambridge, UK‑based biotech cofounded by Nobel laureate Gregory Winter, raised $86 million to advance an antibody program designed to deplete protein deposits in patients with amyloidosis. The financing will support clinical development and manufacturing scale‑up steps for their lead candidate. Company materials described the antibody as aiming to clear extracellular deposits driving organ dysfunction; Immutrin emphasized translational science and Founder‑led leadership as assets in progressing toward clinical endpoints. The round reflects investor interest in antibodies and biologics targeting protein‑aggregation diseases; next milestones will include clinical dose escalation results and safety readouts that define path to registrational studies.